It is currently Sun Dec 21, 2014 10:23 pm

News News of Gilenya

Site map of Gilenya » Forum : Gilenya

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

Gilenya can only gain as Merck scraps rival oral MS drug

Image

Novartis AG's chances of eventually dominating the multibillion dollar multiple-sclerosis market with its new Gilenya pill got a boost Wednesday when Merck KGaA of Germany abandoned attempts to market a rival treatment.

Merck's decision to stop market applications for its MS medicine cladribine and pull the product from Russia and Australia—which comes after the U.S. Food and Drug Administration required more testing to allay safety concerns—means Novartis has the only oral multiple-sclerosis treatment in ...
Read more : Gilenya can only gain as Merck scraps rival oral MS drug | Views : 1037 | Replies : 0


Gilenya, after Tysabri and CCSVI procedure

Hi!

I've been on Tysabri for 2 years, got my CCSVI treatment 11 months ago and now, I switched from Tysabri to Gilenya.

First, I have to say I decided staying on MS drugs, even after my CCSVI intervention. Not because I felt I needed them, because my neurologist insisted and Dr.Zamboni himself ask people to stay under MS med after the treatment.

The CCSVI treatment is the therapeutic option that have been the best ...
Read more : Gilenya, after Tysabri and CCSVI procedure | Views : 3493 | Replies : 10


Approved under PBS in Australia!

It was approved under PBS in Australia today, which means in Australia it will be heavily subsidised by the Government.
Read more : Approved under PBS in Australia! | Views : 1952 | Replies : 8


Comparison of Gilenya with Avonex in relapsing-remitting MS

Image


Summary

Background

In a 12-month phase 3 study in patients with relapsing-remitting multiple sclerosis (RRMS), TRANSFORMS, fingolimod showed greater efficacy on relapse rates and MRI outcomes compared with interferon beta-1a. We had two aims in our extension: to compare year 2 with year 1 in the switched patients to assess the effect of a change from interferon beta-1a to fingolimod, and to compare over 24 months the treatment groups as originally randomised to assess ...
Read more : Comparison of Gilenya with Avonex in relapsing-remitting MS | Views : 1431 | Replies : 0


Cardiovascular effects of oral MS drug Gilenya transient

Cardiovascular effects of oral MS drug Gilenya mostly transient

Image

The first approved oral medication for multiple sclerosis causes transient reductions in heart rate and atrioventricular conduction and a sustained increase in blood pressure, according to investigators who analyzed pooled data from two phase III trials.

The cohorts from the two phase III clinical trials of fingolimod (Gilenya) for relapsing-remitting muscular sclerosis involved 854 patients treated with the currently approved dosage offingolimod (0.5 mg/day), 849 ...
Read more : Cardiovascular effects of oral MS drug Gilenya transient | Views : 1188 | Replies : 0


Reducing the side effects of MS drug, Gilenya

Image

The drug Gilenya (FTY720) is approved for the treatment of multiple sclerosis. Although highly effective it can have serious side effects, including reduced lung function and fluid accumulation in the eye.

Understanding the multiple molecular mechanisms by which the drug affects its target (the S1P receptor) could lead to the development of a drug with the same therapeutic efficacy but reduced side effects.
In this context, a team of researchers, led by Timothy Hla, ...
Read more : Reducing the side effects of MS drug, Gilenya | Views : 1531 | Replies : 0


Oral MS drug Gilenya has yet to show ‘full potential'

Image

Novartis's multiple sclerosis pill Gilenya, which faces a threat from a rival product under development by Biogen Idec Inc, has yet to show its full potential, the Swiss drugmaker’s head of development said.

Gilenya, approved by U.S. regulators last year as the first pill against relapsing forms of multiple sclerosis, may also work in patients with a more severe form of the disease called primary progressive, Novartis’s Trevor Mundel said yesterday in a telephone ...
Read more : Oral MS drug Gilenya has yet to show ‘full potential' | Views : 1078 | Replies : 0


First oral MS drug, Gilenya, now available in UK

Image

A new drug for multiple sclerosis that is twice as effective as the current standard treatment is now available in the UK.

Fingolimod - also known by its brand name Gilenya - is the first pill available to treat MS.


It has been licensed by the European medicines watchdog to treat patients with relapsing-remitting MS who have failed to respond to injections of beta interferon.

Studies show it reduces the relapse rate by 54% ...
Read more : First oral MS drug, Gilenya, now available in UK | Views : 1215 | Replies : 0


Gilenya reduced the risk of MS disability progression

Gilenya reduced the risk of MS disability progression regardless of treatment history or disease severity

Image

A new analysis demonstrated that Gilenya(TM) (fingolimod) reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment history.

This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology (AAN).

"In developing Gilenya, Novartis initiated ...
Read more : Gilenya reduced the risk of MS disability progression | Views : 1197 | Replies : 0


Dubai health authority backs new oral medication for MS

Image

The UAE's Multiple Sclerosis (MS) community is set to become the first in the region to benefit from a new oral medication designed to reduce debilitating symptoms and prevent disability, it was announced today by Dr. Ali Al Sayed, Director of Pharmaceutical Services, Dubai Health Authority (DHA).

Dr. Al Sayed said the new therapy called Gilenya (fingolimod) is now available in the UAE after being approved as a first-line treatment in a number of ...
Read more : Dubai health authority backs new oral medication for MS | Views : 1328 | Replies : 0


 

Login  •  Register


Statistics

Total posts 222333 • Total topics 23091 • Total members 14618


Contact us | Terms of Service